Zn < 2 + >-dependent and deoxyribozyme-responsive nucleic acid PROTAC molecule as well as preparation method and application thereof
By combining Zn2+-dependent nucleic acid PROTAC molecules with ZIF-90 nanoparticles, precise degradation of transcription factors is achieved, the problems of drug delivery difficulties and non-selective toxicity in the prior art are solved, and the therapeutic effect and safety are improved.
Patent Information
- Application Number
- CN202411024617.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
AI Technical Summary
Existing oligonucleotide-based PROTACs have difficulties in drug delivery, poor pharmacokinetics, low potency, and may produce nonselective off-target toxicity, making it difficult to effectively target and degrade transcription factors.
Develop a Zn2+-dependent and deoxyribozyme-responsive nucleic acid PROTAC molecule, through the combination of NBS sequence, thalidomide and DNAzyme, using click chemical reaction to form SUPL with E3 ligase-bound ability and encapsulate it in ZIF-90 In nanoparticles, DNAzyme cleavage is activated by Zn2+ to achieve targeted degradation of transcription factors.
It realizes precise control of targeted protein degradation in cancer cells or tissues, avoids non-specific toxicity, improves the cell utilization and stability of nucleic acid molecules, enhances the drug delivery effect, and verifies it in the tumor-bearing mouse model. In vivo efficacy.
Smart Images

Figure CN118948879A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and particularly relates to a Zn 2+ Nucleic acid-dependent and DNAzyme-responsive PROTAC molecules and preparation methods and applications thereof. Background Art
[0002] Transcription factors (TFs) play a key role in the regulation of gene expression. It is known that dysregulation or mutation of transcription factors can cause a variety of diseases. For example, nuclear factor-κB (NF-κB) is an inducible transcription factor family that regulates many genes involved in various immune and inflammatory response processes and has great potential and selectivity as therapeutic drug targets. However, TFs are traditionally considered to be "undruggable" because they lack processable active sites and present convex and highly positively charged interaction surfaces, which makes them difficult to be targeted by traditional small molecule drugs. The typical treatment method is to develop small molecules that can selectively inhibit the function of these proteins. Although a variety of auxiliary technologies have been developed for drug development, there are still many practical problems to be solved, such as how to achieve efficient drug delivery and targeted druggability of undruggable targets. Therefore, it is very meaningful to develop a controllable drug delivery system that can highly specifically identify and target "undruggable" targets.
[0003] Proteolysis-targeting chimeras (PROTACs) are heterofunctional molecules formed by covalently linking E3 ligands to protein of interest (POI) ligands through linkers, hijacking endogenous E3 ubiquitin ligases and ubiquitin-proteasome system (UPS) to catalyze the degradation of target intracellular proteins (POIs). PROTACs have become a promising targeted therapy for the treatment of various diseases, especially cancer.
[0004] Among them, small molecule-based PROTACs have shown great clinical promise, but how to select a suitable ligand to target TF is still a difficult problem. Oligonucleotide DNA, as the natural binding ligand of TF, is stable in nature, can penetrate tissues, and has low immunogenicity and toxicity. Therefore, nucleic acid-based PROTACs have multiple advantages. It can not only target and bind to undruggable sites, but also flexibly and conveniently replace the DNA part to adapt to targeting other transcription factors. It is a regulatory method with universality, flexibility and high targeting.
[0005] In 2021, Samarasinghe et al. reported the transcription factor targeted chimera (TRAFTACs) technology, which uses the DNA binding ability of transcription factors to induce targeted protein degradation (see Figure 1). Using the developed HaloPROTAC system, Halo Tag-fused dCas9 can recruit VHL. After adding TRAFTAC, the Halo Tag-fused dCas9 protein becomes a bridge between VHL and the transcription factor of interest (TOI), successfully inducing the degradation of NF-kB and Brachyury transcription factors. Figure 1 Schematic diagram of TRAFTAC. As can be seen from the figure: the heterobifunctional dsDNA / CRISPR-RNA chimera (TRAFTAC) recruits the E3 ligase complex through dCas9-HT7 in the presence of halo PROTAC. The heterobifunctional TRAFTAC binds to dCas9-HT7 through its RNA portion, while the dsDNA portion of the chimera binds to the transcription factor of interest (TOI). Addition of halo PROTAC recruits the VHL E3 ligase complex to the vicinity of TOI. TRAFTAC-mediated proximity-induced ubiquitination of TOI for proteasomal degradation.
[0006] In the same year, Liu et al. reported the development of a platform called TF-PROTAC, which selectively degrades related TFs by linking DNA oligonucleotides to E3 ligands through a click reaction. The selectivity of these TF-PROTACs depends on the DNA oligonucleotides used (see Figure 2 ). They developed two VHL-based TF-PROTACs series: NF-κB-PROTAC (dNF-κB) and E2F-PROTAC (dE2F), which can effectively degrade endogenous p65 protein and E2F1 protein in cells, respectively, and subsequently show superior anti-proliferative effects in cells. TF-PROTAC provides a general platform for achieving selective degradation of TFs and also provides a general strategy for targeting most "undruggable" TFs. Figure 2 Schematic diagram of TF-PROTAC strategy. As can be seen in the figure: BCN-modified VHL ligand (VHLL-X-BCN) is incorporated into azide-modified DNA oligomer (N3-ODN) through a copper-free strain-promoted azide-alkyne cycloaddition (SPAAC) reaction to form TF-PROTAC to recruit VHL E3 ubiquitin ligase to ubiquitinate the target transcription factor (TF), which is then degraded by the 26S proteasome.
[0007] Huang and Crew's research groups also developed a similar approach, adding double-stranded oligonucleotides that can recognize TF as binding molecules to POI. They demonstrated that O'PROTACs (oligonucleotide-based PROTACs) against two transcription factors highly associated with cancer, lymphoid enhancer binding factor 1 (LEF1) and ETS-related gene (ERG), successfully promoted the degradation of these proteins, hindered their transcriptional activity, and inhibited the growth of cancer cells in vitro and in vivo (see Figure 3 ). Figure 3 Schematic diagram of the O'PROTACs strategy. The programmable nature of O'PROTACs suggests that this approach is also applicable to disrupting other transcription factors. O'PROTACs can be used not only as a research tool but also as a therapeutic tool to effectively treat diseases such as cancer by targeting DNA binding proteins.
[0008] In the past decade, oligonucleotide-based drug development has become the mainstream of new drug research and development, and some oligonucleotides have been approved by the US Food and Drug Administration (FDA). Nucleotide-based PROTACs provide a scalable platform to achieve selective degradation of TFs and provide a general strategy for targeting most "undruggable" TFs, which can be used to target TFs with known motifs, thereby significantly increasing the spectrum of druggable targets and bringing huge potential therapeutic benefits to patients with various diseases including cancer. These studies have broken through the bottleneck of small molecule inhibitors of transcription factors and achieved selective degradation of targets that are traditionally considered "undruggable", which is of great significance for targeted cancer therapy. However, oligonucleotide-based PROTACs are more difficult to deliver drugs due to the large amount of negative charges carried by their DNA components, and have poor pharmacokinetics and low efficacy. At the same time, through systematic research on nucleic acid PROTAC technology, it was found that this technology usually degrades proteins in cells or tissues in a non-selective manner, which may cause off-target toxicity. Summary of the invention
[0009] The technical problem to be solved by the present invention is to overcome the deficiencies in the prior art and provide a Zn 2+ Nucleic acid PROTAC molecules that are dependent on and respond to DNA enzymes, as well as their preparation methods and applications. Compared with other PROTACS molecules, this nanonucleic acid PROTACS molecule can achieve DNA enzyme response, targeted delivery and selective degradation of transcription factors, and can be used to degrade tumor transcription factors, etc.
[0010] The present invention provides a Zn 2+A nucleic acid PROTAC molecule that is dependent on and responds to a DNAzyme, wherein the nucleic acid PROTAC molecule comprises an NBS sequence, thalidomide, a substrate chain SUP sequence, and a DNAzyme; the NBS sequence is connected to the substrate chain SUP sequence through complementary base pairing, and thalidomide is modified at one end of the substrate chain SUP sequence to form a SUPL capable of binding to an E3 ligase;
[0011] The gene sequence of the substrate chain SUP sequence is shown in SEQ ID NO.1;
[0012] The gene sequence of the NBS sequence is shown in SEQ ID NO.2;
[0013] The gene sequence of the DNAzyme is shown in SEQ ID NO.3.
[0014] The above-mentioned nucleic acid PROTAC molecule is further encapsulated in ZIF-90.
[0015] Based on a general technical concept, the present invention also provides a method for preparing the above-mentioned nucleic acid PROTAC molecule, the preparation method comprising the following steps:
[0016] S1. Synthesis of alkynyl thalidomide;
[0017] S2, coupling the alkynylated thalidomide with the azide-modified substrate chain SUP through a click chemistry reaction to obtain SUPL;
[0018] S3, reacting the SUPL with DNAzyme.
[0019] In the above preparation method, further, S1 specifically comprises:
[0020] S1-1, mixing thalidomide and N-ethyl-N-isopropyl-2-amine to obtain a mixture;
[0021] S1-2, stirring the mixture in dry N,N-dimethylformamide at high temperature, and cooling to room temperature;
[0022] S1-3, extracting the organic phase with ethyl acetate using water, and concentrating under reduced pressure to obtain alkynyl thalidomide.
[0023] In the above preparation method, further, S2 specifically comprises:
[0024] S2-1, after THPTA and CuSO4 are mixed, sodium ascorbate is added to obtain a mixed solution;
[0025] S2-2, adding the alkynylated thalidomide and the azide-modified substrate chain SUP to the mixed solution for incubation;
[0026] S2-3, add sodium acetate and anhydrous ethanol, react under low temperature conditions, centrifuge at high speed, and dissolve with DEPC water.
[0027] In the above preparation method, further, the reaction under low temperature conditions in S3 is specifically: reacting at -20°C for 30 minutes to 1 hour.
[0028] In the above preparation method, further, S3 specifically comprises: reacting 5 μM substrate chain SUPL with 1 μM DNAzyme at 95° C. for 5 min, and naturally cooling to room temperature.
[0029] The above-mentioned preparation method further includes: S4, zinc nitrate dihydrate and the nucleic acid PROTAC molecule are dissolved in deionized water to obtain a mixed solution 1; 2-imidazole carboxaldehyde is dissolved in deionized water by high temperature heating to obtain a mixed solution 2; the mixed solution 2 is vortexed and then added to the mixed solution 1, and the ZIF-90@DzTAC nanoparticles are separated by centrifugation.
[0030] Based on a general technical concept, the present invention also provides a use of the nucleic acid PROTAC molecule in the preparation of targeted anti-tumor drugs.
[0031] Based on a general technical concept, the present invention also provides an application of the nucleic acid PROTAC molecule in the preparation of a drug for degrading tumor transcription factors.
[0032] The above application, further, the method of the application comprises: adding Zn with a final concentration of 2mM to the nucleic acid PROTAC molecule 2+ , react at 37℃ for 2h.
[0033] Compared with the prior art, the advantages of the present invention are:
[0034] (1) The present invention provides a Zn-based 2+ Unlike most small molecule inhibitors that mainly block the catalytic activity of the target enzyme, PROTACs of the present invention are designed to degrade the target protein. This feature provides advantages as well as potential drawbacks. When administered systemically, it may cause uncontrolled degradation of the target protein in normal cells and produce nonspecific toxicity. In order to avoid the above drawbacks, a controllable switch is added to PROTAC to make it react in Zn 2+ Inactive when absent, Zn 2+ When present, it will be activated and degrade the target protein.2+ The dependent DNAzyme can be activated in cancer cells or tissues, precisely controlling targeted protein degradation and eliminating potential nonspecific toxicity.
[0035] (2) The present invention provides a Zn-based 2+ In order to improve the cellular utilization and stability of nucleic acid molecules, ATP-responsive nanoparticles ZIF-90 were introduced for cell delivery. ZIF-90 can dissociate in response to endogenous ATP and release Zn 2+ and encapsulated nucleic acid molecules. Based on the characteristics of oligonucleotide DNA: it can serve as a natural binding ligand for TF, is stable in nature, can penetrate tissues, and has low immunogenicity and toxicity. It can not only target and bind to undruggable sites, but also flexibly and conveniently replace the DNA part to target other transcription factors. Utilizing the characteristics of oligonucleotides, a means of photo-regulated transcription factor degradation with versatility, flexibility and high targeting is designed. In order to solve the problem that oligonucleotide-based PROTACs are more difficult to deliver drugs due to the large amount of negative charge carried by their DNA components, and have poor pharmacokinetics and low efficacy, nanoparticles are introduced to enhance their delivery and drug treatment effects.
[0036] (3) The present invention provides an application of a nucleic acid PROTAC molecule in the preparation of a targeted anti-tumor drug, a DNAzyme-responsive nucleic acid PROTACs molecule DzTAC, which is used to selectively degrade NF-κB, and further constructs a nano-delivery platform ZIF-90@DzTAC to achieve intracellular delivery and self-driven production of Zn 2+ , thereby triggering NF-κB degradation, and verifying the in vivo efficacy of ZIF-90@DzTAC in a tumor-bearing mouse model. ZIF-90@DzTAC can be used as a good and effective self-controlled drug delivery system to efficiently transport functional nucleic acids and self-supply Zn in cells. 2+ The attempt provides a simple method for targeting "undruggable" transcription factors, and also provides a similar paradigm for controlling the activity of PROTACs through functional nucleic acid-mediated reactions, which will inspire many subsequent studies and expand its application in precision medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] In order to make the purpose, technical solution and advantages of the embodiments of the present invention more clear, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.
[0038] Figure 1 Schematic diagram of TRAFTAC in the background technology of the present invention.
[0039] Figure 2Schematic diagram of TF-PROTAC strategy in the background technology of the present invention.
[0040] Figure 3 Schematic diagram of O'PROTACs strategy in the background technology of the present invention.
[0041] Figure 4 This is a schematic diagram of the preparation principle of the near-infrared light-controlled nanonucleic acid PROTACs molecules in Example 1 of the present invention.
[0042] Figure 5 The Zn in Experiment 1 of the present invention 2+ Gel results of inducing DNAzyme to cut the hairpin structure substrate chain.
[0043] Figure 6 The Zn in Experiment 2 of the present invention 2+ Specific cleavage validates gel results.
[0044] Figure 7 The Zn in Experiment 3 of the present invention 2+ The results of the complementary formation of bases within the cleaved substrate strand molecule are shown in Figure a, which is the principle diagram of NBSP formation; Figure b is the fluorescence measurement result.
[0045] Figure 8 This is to verify the Zn 2+ Dependent fluorescence recovery results.
[0046] Fig. 9 This is the result of the streptavidin pull-down experiment combined with NF-κB verification in Experiment 3 of the present invention.
[0047] Fig.10 This is the verification result of generating SUPL by click chemistry of thalidomide and azide-modified substrate chain SUP in Experiment 4 of the present invention. Figure a is a schematic diagram of DzTAC preparation; Figure b is the PAGE result of SUP and SUPL; Figure c is the mass spectrometry result of SUP and SUPL.
[0048] Fig.11 This is the feasibility verification result of DzTAC molecules in cells in Experiment 5 of the present invention. 2+ The fluorescence effect of endogenous p65 degradation mediated by DzTAC is dependent on the degradation of endogenous p65. The data in b are normalized bar graphs (n=3,
[0049] *p<0.05).
[0050] Fig.12 This is the verification result of DzTAC degrading p65 through UPS in Experiment 5 of the present invention.
[0051] Fig.13This is the applicability verification result of DzTAC in Experiment 5 of the present invention.
[0052] Fig.14 The results of the physical property investigation of ZIF-90@DzTAC nanoparticles in Experiment 6 of the present invention are shown in Figure a. The TEM result of ZIF-90@DzTAC (Scale bar = 100 nm); the DLS result of ZIF-90 and ZIF-90@DzTAC; and the Zeta potential characterization result.
[0053] Fig.15 The ATP-dependent results of ZIF-90@DzF in Experiment 7 of the present invention. Figure a shows the ATP-dependent fluorescence intensity detected in the supernatant of ZIF-90@DzF; Figure b shows the fluorescence image of MCF-7 cells treated with Dz / F-SUP-Q and ZIF-90@Dz / F-SUP-Q; scale bar = 10 μm.
[0054] Fig.16 This is the WB result of ZIF-90@DzTAC-induced P65 degradation in Experiment 8 of the present invention.
[0055] Fig.17 These are the results of the cell proliferation experiment after ZIF-90@DzTAC treatment in Experiment 9 of the present invention.
[0056] Fig.18 The colony formation test results of tumor cells treated with ZIF-90@DzTAC in Experiment 10 of the present invention are shown in Figure a. The colony formation test results of tumor cells treated with ZIF-90@DzTAC are shown in Figure b. The statistical analysis is shown in Figure 10 (n=3, *p<0.05).
[0057] Fig.19 The results of the in vivo experiment in Experiment 11 of the present invention are shown in Figure a. The growth curve of tumor volume of mice treated with different methods, the curve of mouse weight in Figure b, and the H&E analysis of tumor in Figure c (scale bar = 100 μm) (n = 5).
[0058] Fig. 20 The results of the experiment 12 of the present invention show that the concentrations of ZIF-90 (a in the figure), ZIF-90@DzTAC (b in the figure), and Zn 2+ Effect on cell viability (c in the figure), error bars represent mean±SD, n=3. DETAILED DESCRIPTION
[0059] The present invention is further described below in conjunction with specific preferred embodiments, but the protection scope of the present invention is not limited thereby. The materials, reagents, and instruments used in the following embodiments can all be purchased from commercial channels. The experimental methods in the following embodiments, unless otherwise specified, are conventional methods in the art.
[0060] Table 1: DNA sequence details
[0061]
[0062] In Table 1 , the bold part represents the core catalytic region of DNAzyme, and the italic part represents the core region of SUP binding to DNAzyme for catalytic cleavage.
[0063] Table 2: Main reagents and materials required for this example
[0064]
[0065]
[0066] Table 3: Main instruments and equipment required for this example
[0067] Device Name Manufacturer Autoclave Harvey Company ELISA reader Molecular Devices Pure water device Millipore Corporation Ice Maker SCOTSMAN <![CDATA[Champ Gel TM 7000 Gel Imaging System]]> Saizhi Venture Technology Co., Ltd. Constant temperature incubator Haimen Qilin Bell Instrument Manufacturing Co., Ltd. <![CDATA[CO2 Incubator]]> Shanghai Yiheng Scientific Instrument Co., Ltd. Fluorescence Spectrometer Edinburgh Company Transmission Electron Microscopy (TEM) JEOL Corporation Particle size analyzer Malvern Instruments Ltd. Automatic cell counter Reward Life Sciences Co., Ltd. Ultra-high speed refrigerated centrifuge Thermo Fisher Scientific Electronic analytical balance Millipore System, Switzerland Ordinary optical microscope Sujing Group Antai Company Vortex mixer Jiangsu Kylin Toledo Company LSM980 Confocal Microscope ZEISS Germany
[0068] Example 1
[0069] A Zn 2+ Dependent and deoxyribozyme-responsive nucleic acid PROTAC molecules: DzTAC, including NBS sequence, thalidomide, and substrate chain SUP. The NBS sequence is connected to the substrate chain SUP through base complementary pairing, and thalidomide is modified at one end of the substrate chain SUP through azide-alkyne click chemistry to form a SUPL with the ability to bind to E3 ligase.
[0070] The gene sequence of SUP is shown in SEQ ID NO.1, specifically:
[0071] TAAAGGACAGTTTTTTGCAGGTAGAGAAGT / rA / GGAAACTATCCCTTAAAGGATTTTCTGTCCTTTAAGGGTTTTTTTTTT-N3.
[0072] The E3 ligase ligand thalidomide is modified at one end of the substrate chain SUP through an azide-alkyne click chemistry reaction to form SUPL with the ability to bind to E3 ligase.
[0073] The gene sequence of the NBS sequence is shown in SEQ ID NO.2, specifically:
[0074] CCCTTAAAGGCCTTTAAGGG-N3.
[0075] When there is no Zn in the system 2+ When the NBS sequence forms a stable structure with the substrate chain SUP through base complementary pairing; by chemically coupling the E3 ligase ligand thalidomide to one end of the azide-modified substrate chain SUP, a SUPL with the ability to bind to the E3 ligase is formed.
[0076] When Zn 2+ When present, it causes DNAzyme to cut SUPL, and the freed chain will replace the original stem (SUPL) of the substrate hairpin to form a structure NBSPL containing NBS in the molecule. NBSPL can bind to recruit NF-κB protein and E3 ligase, and degrade NF-κB protein through ubiquitin-proteasome. The 3' end of NBSP is connected to N3, and the 3' end of NBSPL is connected to the E3 ligase ligand thalidomide.
[0077] The implementation principle can be found in Figure 4 :The construction principle of DzTAC is to use the DNA binding sequence (NBS) of NF-κB, which binds to NF-κB in the cell environment. The DNA binding sequence of NF-κB is disassembled, and there is a stem-loop structure in the middle. The stem-loop is composed of the substrate chain of 8-17DNAzyme, which can be recognized and cut by the catalytic sequence of 8-17DNAzyme; the DNAzyme chain contains the core catalytic motif of 8-17DNAzyme, and there is no Zn in the system. 2+ When Zn is present, it forms a stable structure with the substrate chain SUP through complementary base pairing; by chemically coupling the E3 ligase ligand thalidomide to one end of the azide-modified substrate chain SUP, a SUPL with the ability to bind to the E3 ligase is formed. 2+ When present, it prompts DNAzyme to cut SUPL, and the freed chain will self-replace the original stem (SUPL) of the substrate hairpin to form a structure NBSPL containing NBS in the molecule. NBSPL can bind to recruit NF-κB protein and E3 ligase to degrade NF-κB protein through ubiquitin-proteasome.
[0078] A preparation method of this embodiment first couples the alkyne-modified E3 ligase ligand thalidomide to the 3' end of the azide-modified substrate chain SUP through a click chemistry reaction, thereby forming a substrate chain SUPL that can bind to the E3 ligase. Specifically, the following steps are included:
[0079] (1) Synthesis of alkynyl E3 ligase ligand thalidomide.
[0080] A mixture of thalidomide (276 mg, 1 mmol) and N-ethyl-N-isopropyl-2-amine (129 mg, 1 mmol) was stirred in dry N,N-dimethylformamide (2 mL) at 90 ° C for 12 h. The mixture was cooled to room temperature, 20 mL of water was added and extracted with ethyl acetate (35 mL). The combined organic phases were washed with water (30 mL) and brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude residue was purified by preparative thin layer chromatography to give 2-(2,6-dioxy-3-yl)-4-((2-(2-(propan-2-n-1-yloxy)ethoxy)ethyl)amino)isoindole-1,3-dione (155 mg, yield 39%) as a yellow solid.
[0081] (2) SUPL was obtained by coupling alkynylated thalidomide with the azide-modified substrate chain SUP through click chemistry reaction.
[0082] In a stable mixed solution of 1mM THPTA and 0.2mM CuSO4, 2mM sodium ascorbate was added to reduce CuSO4, and alkynyl thalidomide (1mM) and azide-modified substrate chain SUP (2OD) were added to the mixed solution, incubated at 37°C for 2h, and then sodium acetate (3M, pH 5.2) and 2.5 volumes of anhydrous ethanol were added to the reaction mixture at a ratio of 10:1. The reaction mixture was reacted at -20°C for 30min to 1h, then centrifuged at 15000rpm for 15min, the filter residue was washed with 1mL pre-cooled 75% ethanol and centrifuged at 15000rpm for 2min, and finally dissolved with DEPC water.
[0083] (3) 5 μM substrate chain SUPL was reacted with 1 μM DNAzyme at 95°C for 5 min and then naturally cooled to room temperature to obtain DzTAC.
[0084] Experiment 1: Verification of Zn 2+ Promotes cleavage of DNzyme.
[0085] 1 μM substrate chain SUP and 1 μM corresponding DNAzyme were used, mixed in HEPEs buffer system, reacted in metal incubator at 95°C for 5 min, and naturally cooled to room temperature to obtain a mixture. Subsequently, Zn was added to the above mixture at a final concentration of 2 mM. 2+ The entire reaction system was 10 μL, and the reaction was carried out at 37°C for 2 h. The cleavage effect was verified by 12% polyacrylamide gel electrophoresis (PAGE).
[0086] Figure 5 Zn 2+The gel results of DNAzyme cutting the hairpin structure substrate chain. Lanes Ⅰ and Ⅱ are the substrate chain SUP and DNAzyme single chain respectively; Lane Ⅲ is the substrate chain SUP and DNAzyme; Lane Ⅳ is the Zn 2+ The product chain after cleavage in the presence of Zn 2+ When present, DNAzyme can effectively cleave the substrate chain.
[0087] Experiment 2: Verification of metal ion specificity.
[0088] 1 μM DNAzyme was mixed with 1 μM substrate chain SUP, reacted at 95°C for 5 min, and cooled naturally to room temperature. Subsequently, 0.5 mM Zn 2+ Or the same concentration of Ca 2+ ,Mg 2+ , react at 37°C for 2h and verify by 12% PAGE.
[0089] Figure 6 This is the metal ion specific detection result. It can be seen from the figure that if and only if Zn 2+ DNAzyme can effectively cut the substrate chain when Ca 2+ ,Mg 2+ None of them can effectively cut the substrate chain.
[0090] Experiment 3: Fluorescence recovery experimental verification.
[0091] 3.1 Zn 2+ Verification of base complementation within the cleaved substrate strand molecule:
[0092] Experimental group: 1 μM DNAzyme was mixed with 1 μM substrate chain (FAM-SUP-BHQ), reacted at 95°C for 5 min, and naturally cooled to room temperature to obtain a mixed solution. Subsequently, 0.5 mM Zn 2+ , react at 37°C for 2 h, and add NF-κB protein.
[0093] Control group: 1 μM DNAzyme was mixed with 1 μM substrate chain (FAM-SUP-BHQ), reacted at 95°C for 5 min, and naturally cooled to room temperature to obtain a mixed solution.
[0094] The above experimental group, positive control group and negative control group were subjected to fluorescence detection respectively.
[0095] The experimental results can be found in Figure 7The a in the figure is the principle diagram of NBSP formation; it can be seen from the figure that the two ends of the substrate chain SUP are labeled with a fluorophore and a quencher (denoted as Q-SUP-F). After the substrate chain SUP is cut, it can form a nucleic acid chain that specifically recruits NF-κB protein by intramolecular base complementary pairing through fluorescence detection. 2+ After the cutting, the released chains are complemented within the molecules, which promotes the formation of NBSP, resulting in the displacement and release of the quenched chain and the recovery of fluorescence.
[0096] Figure b shows the fluorescence detection results. It can be seen from the figure that sufficient fluorescence enhancement was measured within 2 hours, confirming the formation of NBSH in response to DNAzyme.
[0097] 3.2. Zn was verified in living cells 2+ Dependent fluorescence recovery: Dz / F-SUH-Q (i.e., 1 μM DNAzyme and 1 μM FAM-SUP-BHQ reacted at 95°C for 5 min and naturally cooled to room temperature to obtain a mixed solution) was transfected into MCF-7 breast cancer cells by lipofectamine 3000. The Zn 2+ Dependent fluorescence recovery. The specific experimental method is:
[0098] The assembled DNAzyme and substrate chain (FAM-SUP-BHQ) were mixed and transfected into MCF-7 breast cancer cells. After the culture medium was replaced with complete medium, 0.5 mM Zn was added to the cell system. 2+ The cells were cultured in a 37°C incubator for 2 h, washed with PBS, and the nuclear dye Hoechst 33258 was added. The cells were incubated at room temperature for 5 min, and confocal imaging was performed using an LSM980 confocal microscope.
[0099] The experimental results can be found in Figure 8 The left picture shows the Zn 2+ Fluorescence images in the presence or absence of Zn, scale bar = 10 μm. 2+ , one group without Zn 2+ The confocal results are as follows Figure 8 As shown, it was found that adding Zn 2+ After that, the obvious fluorescence signal was restored, proving that the substrate chain SUP we designed is Zn 2+ It is dependent on the DNA and effectively promotes DNAzyme cleavage, resulting in fluorescence recovery.
[0100] 3.3 To confirm the binding of NBSH to NF-κB, we performed protein pull-down experiments using streptavidin-coated microspheres to capture biotinylated SUHB and its binding proteins.
[0101] The specific experimental process is as follows: MCF-7 cells in the logarithmic growth phase in a six-well plate were randomly divided into groups. The control group was not treated. The experimental group: Lipofectamine 3000 reagent was transfected with 20 μL of biotin-labeled substrate chain (10 μM) and 4 μL of DNAzyme (10 μM). The cells were cultured in a cell culture incubator for 6 hours and the culture medium was replaced. The cells were further cultured in complete culture medium for 12 hours. The cells were collected and lysed with Passive Lysis 5× Buffer (containing protease inhibitors and phosphatase inhibitors), and each 80 μL of extracted protein was incubated with 20 μL of streptavidin-coated magnetic beads at 4°C with shaking overnight. The cells were separated using a magnetic stand and then washed three times with lysis buffer. Then the samples were added with protein loading buffer, heated at 95°C for 5 minutes on a metal incubator, and finally separated using 10% SDS-PAGE gradient, and analyzed by immunoblotting with a single antibody. The specific steps were operated according to the instructions of the immunoprecipitation kit (protein A+G magnetic beads method).
[0102] Fig. 9 The results of the streptavidin pull-down experiment combined with NF-κB were verified. As can be seen from the figure: through immunoblotting (IB) detection of NF-κB P65 subunit, the formation of biotinylated NBSH induced by DNAzyme in the presence of zinc ions successfully enriched NF-κB, confirming the response of DNAzyme to NF-κB.
[0103] Experiment 4: Investigate the principle of generating SUPL through click chemistry of thalidomide and azide-modified substrate chain SUP.
[0104] First, add 2mL 5×TBE buffer solution, 3.93mL deionized water, 70μL 10% APS, 4mL 30% acrylamide-methylenebisacrylamide and 7μL TEMED solution to a 50mL centrifuge tube, vortex and mix to prepare a 12% polyacrylamide gel. Add 1×Tris-Borate-EDTA buffer (TBE) to the electrophoresis tank, add 10μL of sample and 2μL 6×loading buffer to the corresponding channel, and set the electrophoresis parameters to 120V and 60min. Then, place the gel in a newly prepared nucleic acid stain (a uniform mixture of 2.5mL 5×TBE, 22.5mL deionized water, and 5μL GelRed) for 30min and use ChampGel TM 7000 system to image the gel. Observe the gel electrophoresis results of the reaction samples.
[0105] Fig.10 The results of verifying the generation of SUPL by click chemistry from thalidomide and azide-modified substrate chain SUP. Figure a shows the principle of generating SUPL by click chemistry from thalidomide and azide-modified substrate chain SUP: the alkyne-modified E3 ligase ligand thalidomide (pentagram) is coupled to the 3' end of the azide-modified substrate chain SUP through click chemistry reaction, thereby forming a substrate chain SUPL that can bind to the E3 ligase. Figure b and figure c are gel electrophoresis and mass spectrometry, respectively. The figure confirms that thalidomide can be successfully modified on SUP to synthesize SUPL.
[0106] Example 2
[0107] An application of the DzTAC molecule of Example 1 in the preparation of a targeted drug is to transfect the DzTAC molecule into MCF-7 cells to degrade NF-κB. The specific application method is:
[0108] (1) Material preparation: Human breast cancer cells (MCF-7) were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). MCF-7 cells were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin / streptomycin. The culture medium was prepared according to Table 4. The temperature of the incubator was set at 37°C and the CO2 content was 5%.
[0109] Table 4: DMEM medium configuration with 10% fetal bovine serum (500 mL as an example)
[0110] Reagent name Dosage FBS 50mL DMEM 445mL Penicillin / Streptomycin mixture 5mL
[0111] (2) Cell recovery: Open the water bath in advance and preheat the water to 37°C. Disinfect the clean bench with ultraviolet light for 30 minutes in advance. Clean the clean bench with 75% alcohol cotton balls, then take out the frozen cells, quickly put them into a 37°C water bath, and quickly shake them to dissolve them. Centrifuge them in a centrifuge at 1200 rpm for 3 minutes, then operate in the cell clean bench, aspirate the freezing solution, first add culture medium to the cryopreservation tube to allow the cells to adapt to the culture medium environment, then add an appropriate amount of culture medium and gently pipette to mix several times, then transfer to a 10 cm culture dish with 5 mL-8 mL of culture medium, pipette to mix, observe under a microscope, and culture in a cell culture incubator. Change the medium after 24 hours.
[0112] (3) Cell passaging: Turn on the ultraviolet light of the clean bench for 30 minutes in advance for disinfection, and wipe the clean bench with 75% alcohol cotton balls. When the cell density reaches 80%-90%, cell passaging can be carried out at a ratio of 1:2 or 1:3. Aspirate the old culture medium, wash with PBS, add trypsin and place in a 37℃ cell culture incubator for 1-2 minutes. Observe under a microscope. When the cell morphology becomes round, digestion is terminated. Transfer to a 1.5mL centrifuge tube, centrifuge at 1200rpm for 3 minutes, replace with new culture medium and resuspend, divide it into new cell culture dishes, and continue to culture in the cell culture incubator.
[0113] (4) Cell cryopreservation: The previous operation is the same as cell passaging. After digestion, centrifuge the cells and collect the cell fluid in a 2mL centrifuge tube. Centrifuge at 1200rpm for 3min. After centrifugation, discard the supernatant, add the freezing solution and blow evenly to make a cell suspension and transfer it to the cryopreservation tube. Mark the time, cell name, and name of the cryopreservation person on the cryopreservation tube. First place it in a 4℃ refrigerator for 30min, then place it in a -20℃ refrigerator for 1h, and store it in a -80℃ refrigerator.
[0114] (4) Cell transfection: Lipofectamine 3000 reagent was used to transfect DzTAC molecules into MCF-7 cells growing in the logarithmic phase in the well plate. The cells were placed in an incubator for transfection for 6 h, and then the cells were washed three times with PBS and continued to be cultured in fresh culture medium. The cells were then collected and processed.
[0115] (5) When treating DzTAC, 10 μL SUPL (30 μM) and 10 μL DNAzyme (6 μM) were added to each 1 mL of culture medium and transfected into MCF-7 cells for 6 h. The cells were washed three times and then treated with 0.5 mM Zn 2+ Incubate for 2 hours.
[0116] Experiment 5: Investigate the expression level of NF-κB subunit p65 protein in MCF-7 cells transfected with Dz / SUPL.
[0117] 5.1. Feasibility verification of DzTAC molecules in cells: When treating DzTAC, 10 μL SUPL (30 μM) and 10 μL DNAzyme (6 μM) were added to each 1 mL of culture medium to transfect MCF-7 cells for 6 hours, the cells were washed three times, and then 0.5 mM Zn 2+ After 2 hours of incubation, the cells were washed with PBS and then used for subsequent protein determination experiments.
[0118] Results Fig.11 . a in the figure is Zn 2+ The fluorescence effect of endogenous p65 degradation mediated by DzTAC is dependent on Zn 2+Statistical analysis of DzTAC-mediated degradation of endogenous p65 (n=3, *p<0.05).
[0119] The figure shows that the P65 level was significantly reduced only in the Dz / SUPL-transfected MCF-7 cells treated with zinc ions, proving that the DzTAC molecule can successfully respond to Zn 2+ It promotes the cleavage and binding of DNAzyme to degrade the NF-κB subunit p65 protein.
[0120] 5.2. Verification of DzTAC degradation of p65 through UPS: Proteasome inhibitor MG132 was used to inhibit protein hydrolysis: In the proteasome inhibition experiment, MCF-7 cells were pre-incubated with 1, 5 or 10 μM MG132 for 12 h; after PBS washing, fresh culture medium containing ZIF-90@DzTAC (36 μg / mL) was added to MCF-7 cells, and subsequent cell lysis was performed after incubation for 8 h.
[0121] Results Fig.12 DzTAC was verified by UPS degradation of p65. As can be seen from the figure: MG132 at a concentration of 1 μM or higher can effectively inhibit the degradation of NF-κB.
[0122] 5.3. Applicability verification of DzTAC: MCF-7 cells were pre-incubated with alkynyl-modified thalidomide (6 μL 60 mM added to 500 μL fresh medium) for 12 h; after washing with PBS, fresh medium containing ZIF-90@DzTAC (36 μg / mL) was added to MCF-7 cells and incubated for 8 h before subsequent cell lysis.
[0123] Fig.13 The results of DzTAC applicability verification are shown in the figure. It can be seen from the figure that the addition of excessive thalidomide can protect NF-κB from degradation, confirming that DzTAC-mediated NF-κB degradation depends on the proteomic pathway. When HeLa cells are treated under the same conditions, the expression of P65 is also significantly reduced, proving the applicability of DzTAC.
[0124] Example 3
[0125] A ZIF-90@DzTAC nanoparticle of the present invention, the preparation method thereof comprises the following steps:
[0126] (1) Preparation of nanoparticles: 1 mg of zinc nitrate dihydrate (Zn(CH3COO)2·2H2O) and 250 nM DzTAC were dissolved in 2 mL of deionized water to obtain a mixed solution 1. 19.2 mg of 2-imidazolecarboxaldehyde (2-ICA) was dissolved in 2 mL of deionized water and heated at 95°C for 5 min to obtain a mixed solution 2 after complete dissolution.
[0127] (2) Mixture 2 was transferred to a 15 mL centrifuge tube, and after a stable vortex was formed on a vortex shaker, mixture 1 was added to the center of the vortex, shaken for 3 min, and then centrifuged at 12000 rpm for 10 min at 4 °C, the supernatant was discarded, and the precipitate was washed three times with deionized water, and centrifuged again under the same conditions to obtain ZIF-90@DzTAC nanoparticles. These solid nanoparticles were obtained by vacuum drying.
[0128] Experiment 6: Investigate the physical properties of ZIF-90@DzTAC nanoparticles.
[0129] The physical properties of ZIF-90@DzTAC nanoparticles were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS) and zeta potential analysis. Fig.14 .
[0130] Fig.14 The results of the physical property investigation of ZIF-90@DzTAC nanoparticles in Experiment 6 of the present invention are shown in Figure a. The TEM result of ZIF-90@DzTAC (Scale bar = 100 nm); the DLS result of ZIF-90 and ZIF-90@DzTAC; and the Zeta potential characterization result of ZIF-90 and ZIF-90@DzTAC are shown in Figure c.
[0131] As can be seen from the figure: DLS measurement shows that after DzTAC encapsulation, the hydrodynamic diameter of ZIF-90NPs increased from 98.5±7.2nm to 237.6±17.4nm. The encapsulation of negatively charged DzTAC leads to a decrease in the positive charge on the surface of the nanoparticles and a decrease in the zeta potential.
[0132] Experiment 7: Investigate the release of ATP-responsive ZIF-90 nanoparticles.
[0133] The FAM-labeled substrate chain SUPF (substrate hairpin FAM) and DNAzyme were encapsulated into ZIF-90 to synthesize solid ZIF-90@Dz / SUPF according to the above method, and then 1mM, 2mM, 5mM, and 10mM ATP solutions were added. After reacting at 37°C for 1h, the mixture was centrifuged at 12000rpm at 4°C for 10min, the supernatant was taken, and the fluorescence intensity in the supernatant was detected using a fluorescence spectrometer.
[0134] Fig.15The ATP-dependent results of ZIF-90@DzF. The a in the figure is the fluorescence intensity result, and the b in the figure is the fluorescence image of MCF-7 cells treated with Dz / F-SUP-Q and ZIF-90@Dz / F-SUP-Q. Scale bar = 10μm. It can be seen from the figure that: with the increase of ATP concentration, an ATP-dependent fluorescence increase was detected in the supernatant of ZIF-90@DzF. Similarly, confocal imaging in the cells observed obvious fluorescence, which proves that ZIF-90 can successfully respond to ATP dissociation and release the encapsulated nucleic acid molecules, proving the effective intracellular delivery ability of ZIF-90, which can be used for subsequent experiments.
[0135] Comparative Example 1
[0136] According to the method of Example 2, the FAM-labeled substrate chain SUPF was encapsulated into ZIF-90 and synthesized according to the above method to obtain ZIF-90@Dz / SUPF (ZIF-90@Dz / SUPF is a FAM group connected to the SUP chain) solid.
[0137] The specific SUP-FAM gene sequence is:
[0138] FAM-TAAAGGACAGTTTTTTGCAGGTAGAGAAGT / rA / GGAAACTATCCCTTAAAGGATTTTCTGTCCTTTAAGGGTTTTTTTTTT.
[0139] Experiment 8: Evaluation of the ability of ZIF-90@DzTAC to mediate NF-κB degradation
[0140] The ZIF-90@DzTAC nanoparticles of Example 3 and the ZIF-90@Dz / SUPF of Comparative Example 1 were subjected to Western blot to investigate the ability of ZIF-90@DzTAC to mediate NF-κB degradation. The specific experimental process is as follows:
[0141] 8.1. Extract protein from cells: Take out the pre-treated cells, aspirate the culture medium, wash the cells with pre-cooled PBS, repeat three times. Add 10μL PMSF to 1mL lysis buffer, lyse on ice for 30min, scrape the cells with a cell scraper, transfer to a 1.5mL centrifuge tube, centrifuge at 4℃15000rpm for 15min (pre-cool the centrifuge in advance). Aspirate the supernatant after centrifugation for the next step of protein concentration determination (the whole process should be done on ice).
[0142] 8.2. Determine protein concentration: According to the instructions of the BCA protein concentration kit, measure the protein absorbance on the microplate reader on a 96-well plate, and then calculate to determine the concentration of the extracted protein. Add protein 5x Loading Buffer to the extracted protein sample to dilute the sample to the same concentration and volume, shake and centrifuge, and heat at 95℃ for 10 minutes to prepare the protein sample (it can be stored in a 4℃ refrigerator for one week).
[0143] 8.3. SDS-PAGE electrophoresis:
[0144] Prepare 10% SDS-PAGE separation gel: 6.7 mL acrylamide / methylenebisacrylamide 30% solution (29:1), 5 mL 1.5 M Tris (pH 8.8), 0.2 mL 10% SDS, 0.2 mL 10% ammonium persulfate (APS), 0.08 mL tetramethyldiethylamine (TEMED), and 7.9 mL pure water.
[0145] Prepare 10% SDS-PAGE stacking gel: 0.83 mL acrylamide / methylene bisacrylamide 30% solution (29:1), 0.63 mL 1.5 M Tris (pH 6.8), 0.05 mL 10% SDS, 0.05 mL 10% ammonium persulfate (APS), 3.4 m.
[0146] Pure water was used to add the sample into the wells, with 2 μL of 10Kd-250 Kd protein marker at both ends, and 1x running buffer was added into the electrophoresis tank. The electrophoresis conditions were 70V for 30min (concentrating gel) and 150V for 60min (separating gel).
[0147] 8.4. Transfer: Place the protein gel in the pre-cooled transfer solution, and place the sponge, filter paper, protein gel, nitrocellulose membrane (NC membrane), filter paper, and sponge in the "sandwich" structure in the splint in sequence. Press to drive away the bubbles, pour the pre-cooled transfer solution into the transfer tank, and place the splint into the transfer tank. The entire system should ensure that electrophoresis is performed in a low temperature environment. The electrophoresis conditions are 300mA 80min.
[0148] 8.5. Primary antibody incubation: The membrane was blocked in 5% BSA solution with shaking at room temperature for 2 h, washed three times with 1×TBST, each time for 10 min, and then the corresponding primary antibody was added and incubated at 4°C overnight.
[0149] 8.6. Secondary antibody incubation and imaging: After removing the membrane, wash it three times with 1×TBST, 10 min each time, add HRP-conjugated secondary antibody and incubate at room temperature for 1 h, wash it three times with 1×TBST, use the freshly prepared ECL developer, use the gel imaging system to image the nitrocellulose membrane, and analyze the data with Image J software.
[0150] Results Fig.16 . Fig.16 The WB results of ZIF90@DzTAC and ZIF-90@Dz / SUP show that NF-κB is degraded and the expression of P65 is reduced in the ZIF90@DzTAC group.
[0151] Experiment 9: Cell proliferation experiment.
[0152] (1) MCF-7 cells were incubated with ZIF-90@DzTAC and ZIF-90 nanoparticles for 8 h in advance, washed with PBS, added with complete culture medium and cultured in an incubator for 12 h.
[0153] (2) Digest the cells with trypsin to prepare a cell suspension and count them using a cell counter. Inoculate 10 cells in a 12-well plate. 5 Each experimental group was cultured in 37°C incubator with 10% FBS culture medium.
[0154] (3) MCF-7 cells were digested at the same time every other day, resuspended in complete medium, and counted. After the counting was completed, all the cells in each well of each group were re-plated into a 12-well plate. This step was repeated for three consecutive days to obtain the cell growth count for three consecutive days. Statistical analysis was performed using GraphPad prism8 to evaluate cell viability.
[0155] Results Fig.17 Through cell proliferation experiments, it was found that compared with the ZIF-90@DzTAC control group, ZIF-90 or ZIF-90@Dz / SUP treatment had no significant difference in the effect on MCF-7 cells. Only ZIF-90@DzTAC treatment had a significant growth inhibitory effect on MCF-7 cells, proving that ZIF-90@DzTAC can degrade P65 and thus inhibit the growth of tumor cells.
[0156] Experiment 10: Colony formation experiment of tumor cells treated with ZIF-90@DzTAC.
[0157] MCF-7 cells were plated in 6-well plates and cultured in advance. When the cell density reached about 70%-80%, ZIF-90@DzTAC (36 μg / mL) and ZIF-90 (36 μg / mL) were added respectively and incubated in a 37°C incubator for 8 h. The cells were washed three times with PBS and cultured in fresh culture medium for another 12 h, and then the cells were collected for processing.
[0158] (1) Cell infection and inoculation: Digest each group of cells with trypsin to prepare a cell suspension, and count the cells using a cell counter. Inoculate 1000 cells / well in a 6-well plate, set up 3 replicate wells for each experimental group, and culture in a 37°C incubator with a 30% FBS culture medium.
[0159] (2) Observe the growth status of cells and change the medium every 3 days. When the number of cell clones grows to about 50, discard the supernatant and wash the cells with PBS.
[0160] (3) Add 1 mL of 4% paraformaldehyde to each well, fix the cells in a 4°C refrigerator for 60 min, and then wash with PBS.
[0161] (4) Add 1 mL of crystal violet stain to each well and stain for 2 min.
[0162] (5) Finally, the cells were washed several times with deionized water, dried, photographed, and counted using Image J.
[0163] Fig.18 The results of the colony formation experiment of tumor cells treated with ZIF-90@DzTAC in Experiment 10 of the present invention are shown in Figure a. The colony formation experiment results of tumor cells treated with ZIF-90@DzTAC are shown in Figure b. The statistical analysis (n=3, *p<0.05) is shown in the figure. It can be seen from the figure that the cells treated with ZIF-90@DzTAC grow and proliferate slowly, and the number of cell clones is significantly reduced, while the tumor cells in the ZIF-90, ZIF-90@Dz / SUP and blank groups grow and proliferate normally. It is proved that the ZIF-90@DzTAC system can inhibit the growth of tumor cells and thus inhibit tumor occurrence by degrading the NF-κB protein of the cells.
[0164] Experiment 11: In vivo experiment
[0165] Experimental mice: Balb / c female nude mice (6 weeks old) were purchased from Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd. and raised in the Experimental Animal Center of the Institute of Life and Medical Sciences, Hunan University.
[0166] Construction of breast cancer tumor model: MCF-7 cells were digested with trypsin in advance, centrifuged at 1200 rpm for 3 min, and the supernatant was discarded. Cell suspension was made with PBS buffer, placed on ice, and the cells were counted using a cell counter. 7 MCF-7 cells were injected subcutaneously into the right hind leg of nude mice. After about a week of growth, the tumor volume grew to 90-120 mm. 3 , and obtained a breast cancer tumor mouse model.
[0167] In vivo anticancer study: MCF-7 tumor-bearing mice were randomly divided into 4 groups, 5 mice in each group, and the following samples were injected into the tail vein: ZIF-90 (75μL, 0.4mg / mL), DOX (50μL, 1μg / mL), ZIF-90@DzTAC (75μL, 0.4mg / mL), and ZIF-90@DzTAC+DOX (0.75μL, 0.4mg / mL+50μL 1μg / mL). The corresponding drugs were injected into the tail vein every other day, and the tumor volume (V=a*b*c / 2, where a is length, b is width, and c is height) and body weight were monitored every three days. The monitoring was continued for 18 days, and the mice were killed after 18 days. The tumors were taken and the final body weight was recorded. Then, after embedding, sectioning (8μm), and staining with H&E, the tissues were observed under an optical microscope.
[0168] The in vivo antitumor efficacy of ZIF-90@DzTAC was evaluated. It is well known that NF-κB activation can promote chemotherapeutic resistance in cancer cells through genes involved in proliferation and anti-apoptosis. Therefore, we combined the chemotherapeutic drug DOX to enhance doxorubicin-based chemotherapy in tumor-bearing mice. A mouse xenograft model of MCF-7 cell-derived tumors was established. Mice were injected with 30 mg ZIF-90@DzTAC via the tail vein every two days after 6 days of tumor implantation. The mice were randomly divided into 4 groups with 5 mice in each group, and the body weight and tumor volume of the mice were monitored every 3 days and HE staining was performed. The monitoring was continuous for 18 days.
[0169] Fig.19 These are the results of the in vivo experiments in Experiment 11 of the present invention. Figure a is the tumor volume growth curve of mice treated differently, and Figure b is the mouse weight curve; Figure c is the H&E analysis of the tumor (scale bar = 100 μm) (n = 5). It can be seen from the figure that DOX+ZIF-90@DzTAC significantly inhibits tumor growth (b). The HE staining of the ZIF-90@DzTAC+Dox group in the tumor observed an obvious tissue killing effect c), and no obvious physiological abnormalities were observed in other major organs, proving that ZIF-90@DzTAC+DOX treatment significantly inhibited tumor growth, confirming the anti-tumor effect of ZIF synergistic treatment.
[0170] Experiment 12: Cytotoxicity experiment.
[0171] MCF-7 cells were seeded in 96-well plates in advance and cultured for 24 h before adding different concentrations of Zn 2+(0.1mM, 0.2mM, 0.5mM, 1mM) and different concentrations (19μg / mL, 66μg / mL, 114μg / mL, 150μg / mL) of ZIF-90 and ZIF-90@DzTAC, with 5 replicate wells in each group. After 2h incubation in a cell culture incubator, the cells were washed with PBS, and then fresh culture medium containing 10% CCK8 reagent was added, and the cells were cultured in a cell culture incubator for 1h. Finally, the absorbance at 450nm was detected using an ELISA reader.
[0172] Results Fig. 20 In the experiment 11 of the present invention, different concentrations of ZIF-90 (a in the figure), ZIF-90@DzTAC (b in the figure), and Zn 2+ Effects on cell viability (c in the figure), error bars represent mean ± SD, n = 3. As can be seen from the figure; 0.5 mM Zn 2+ , ZIF-90 and ZIF-90@DzTAC at 60 μg / mL and below had less cytotoxicity, demonstrating their good biocompatibility.
[0173] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as above in the preferred embodiment, it is not used to limit the present invention. Any technician familiar with the art can make many possible changes and modifications to the technical solution of the present invention by using the methods and technical contents disclosed above without departing from the spirit and technical solution of the present invention, or modify it into an equivalent embodiment of equivalent changes. Therefore, any simple modification, equivalent replacement, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention, still fall within the scope of protection of the technical solution of the present invention.
Claims
1. A Zn 2+ A nucleic acid-dependent and DNAzyme-responsive PROTAC molecule, characterized in that The nucleic acid PROTAC molecule includes an NBS sequence, thalidomide, a substrate chain SUP sequence and a DNAzyme; the NBS sequence is connected to the substrate chain SUP sequence through base complementary pairing, and thalidomide is modified at one end of the substrate chain SUP sequence to form a SUPL with the ability to bind to an E3 ligase; The gene sequence of the substrate chain SUP sequence is shown in SEQ ID NO.1; The gene sequence of the NBS sequence is shown in SEQ ID NO.2; The gene sequence of the DNAzyme is shown in SEQ ID NO.
3.
2. The nucleic acid PROTAC molecule according to claim 1, characterized in that It also includes ZIF-90, and the nucleic acid PROTAC molecule is encapsulated in ZIF-90.
3. The nucleic acid PROTAC molecule according to claim 1 or 2, characterized in that A fluorescent group is connected to the DNAzyme; And / or, a fluorescent group or biotin is connected to the SUP sequence of the substrate chain.
4. A method for preparing a nucleic acid PROTAC molecule according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: S1. Synthesis of alkynyl thalidomide; S2, coupling the alkynylated thalidomide with the azide-modified substrate chain SUP through a click chemistry reaction to obtain SUPL; S3, reacting the SUPL with DNAzyme.
5. The preparation method according to claim 4, characterized in that: The S1 specifically includes: S1-1, mixing thalidomide and N-ethyl-N-isopropyl-2-amine to obtain a mixture; S1-2, stirring the mixture in dry N,N-dimethylformamide at high temperature, and cooling to room temperature; S1-3, extracting the organic phase with ethyl acetate using water, and concentrating under reduced pressure to obtain alkynyl thalidomide; And / or, S2 specifically includes: S2-1, after THPTA and CuSO4 are mixed, sodium ascorbate is added to obtain a mixed solution; S2-2, adding the alkynylated thalidomide and the azide-modified substrate chain SUP to the mixed solution for incubation; S2-3, add sodium acetate and anhydrous ethanol, react under low temperature conditions, centrifuge at high speed, and dissolve with DEPC water.
6. The preparation method according to claim 4, characterized in that: The S3 specifically includes: reacting 5 μM substrate chain SUPL with 1 μM DNAzyme at 95° C. for 5 min, and naturally cooling to room temperature.
7. The preparation method according to any one of claims 4 to 6, characterized in that: The preparation method further comprises: S4, zinc nitrate dihydrate and the nucleic acid PROTAC molecule are dissolved in deionized water to obtain a mixed solution 1; 2-imidazole carboxaldehyde is dissolved in deionized water at high temperature to obtain a mixed solution 2; the mixed solution 2 is vortexed and then added to the mixed solution 1, and the ZIF-90@DzTAC nanoparticles are separated by centrifugation.
8. Use of the nucleic acid PROTAC molecule according to any one of claims 1 to 3 in the preparation of targeted anti-tumor drugs.
9. Use of the nucleic acid PROTAC molecule according to any one of claims 1 to 3 in the preparation of a drug for degrading tumor transcription factors.
10. The use according to claim 8 or 9, characterized in that: The application method comprises: adding Zn with a final concentration of 2 mM to the nucleic acid PROTAC molecule; 2+ , react at 37℃ for 2h.
